This study aims to compare efficacy of dose dense and conventionally dosed paclitaxel-carboplatin regimens in the first-line treatment of epithelial ovarian cancer (EOC). We evaluated the medical records of women with EOC followed in Zekai Tahir Burak Women’s Health Training and Research Hospital between 2007-2019 retrospectively. The patients with Eastern Cooperative Oncology Group Performance Status of 0-1-2, and stages of IC-IV, without previous treatments, who had undergone primary cytoreductive surgery were included. All patients had received either dose dense paclitaxel-carboplatin (paclitaxel 80 mg/m2 given on days 1, 8, and 15 plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) or conventionally dosed paclitaxel-carboplatin (paclitaxel 175 mg/m2 plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) regimens in the first line treatment. Baseline clinicopathological features, progression-free survival, and overall survival were evaluated. This study included data of 133 patients. Forty patients had received dose dense regimen while 93 had conventionally dosed regimen. Median progression-free survival of the dose dense group [34.4 months (31.7 - 37.03)] was significantly longer than the conventional group [25.5 months (19.9-30.9)] [HR= 0. 55 (95% CI, 0.31 - 0.95), p= 0.03]. Median overall survival was 88.2 months (28.3 - 148.3) in the dose dense group and 76.5 months (63.3 - 89.7) in conventional group (p= 0.102).We have found improved progression-free survival in the first-line treatment of EOC with dose dense regimen compared to conventionally dosed regimen. Overall survival was longer in the dose dense group despite being not significant.